Skip to content
Open access

Advanced Cytometry Techniques for Immune-Based Therapy Analysis 2308503

Jul 2026 · Journal of Immunology · Vol 215 · 0 citations

TL;DR

The combined use of an advanced panel builder and the iQue® HTS Platform streamlines the creation of flexible panels for profiling immune cells, suitable for the generation of HTS data in 96- or 384- well throughput.

Abstract

As interest in CAR-T cells and immune-based oncology therapies rises, efficient phenotyping of cell therapy products becomes essential. This involves analyzing surface markers associated with cell type characteristics. To address this need, tools for panel design and instruments for cell interrogation must be compatible. This study highlights the combined use of an advanced panel builder to simplify assay creation with quantification using the iQue® HTS Cytometer Platform. A comprehensive T cell panel was developed using the panel builder, featuring phenotype, activation, exhaustion, and memory markers, with a cell viability indicator. Two panels were created: one for iQue® 3 and a more extensive panel for iQue® 5, utilizing the enhanced laser features. Compensation particles were used to calculate spillover values using iQue Forecyt® software before applying the panel to immune cells. Human PBMCs were cultured in RPMI 1640 media with 10% serum and IL-2, with or without CD3/CD28 activation beads to activate the T cell population. Cells were collected and analyzed in a 96-well plate at 48- and 72-hours post-activation. CD3+, CD4+, and CD8+ T cell populations were gated, and their markers were characterized. The iQue® 5 enhanced capabilities allowed for more comprehensive analysis of activation, exhaustion, and memory markers from one sample. Data showed an increase in activation markers, and a transient increase in exhaustion marker expression over time. In summary, the panel design tool, and the iQue® HTS Platform streamlines the creation of flexible panels for profiling immune cells. This combined approach is suitable for the generation of HTS data in 96- or 384- well throughput. The panel can be enhanced to include cytokine profiling with the iQue Qbead® immunoassay portfolio, utilizing the ability to track cell and bead populations within the same sample. n/a Translational and Interventional Immunology (TI)

Read PDF

Similar papers

Sep 2026

A Multimodal Framework to Assess Patient-Derived Colon Tumor Organoid-Immune Cell Co-cultures.

T cells play a key role in cancer immunotherapy, and understanding their interactions with tumors is essential for developing novel immunotherapies. This protocol describes the step-by-step workflow for establishing colorectal cancer patient-derived organoids (PDOs) from our biobank and developing autologous PDO-T cell...

Mahshid Mohammadi, Nityanand Srivastava, Muzaffer Ahmed Bhat et al. · 0 citations
Open access Sep 2026

The phenotypic heterogeneity of tumor-derived cells in the bloodstream of pancreatic cancer patients

These findings provide a comprehensive characterization of CTCs and CTACs in PC using a multiplex biomarker panel associated with calcium signaling and immune checkpoint pathways, highlighting the pronounced heterogeneity and potential clinical relevance of these circulating cell populations.

Chrysoula Tagari, Karolina Mangani, Michael Gogolides et al. · 0 citations
Open access Sep 2026

A Research-Integrated Curriculum on CAR-T Cell Therapy

Chimeric antigen receptor (CAR) T cells are patient-derived T cells engineered to recognize specific antigens on malignant cells, representing a major breakthrough in personalized cancer immunotherapy. While CAR-T cell therapy is an established treatment for relapsed or refractory hematologic malignancies, understandin...

Youan H. Khan, Lauren Rice, Melissa C. Srougi · 0 citations
Open access Jun 2026

Optimized procurement of cancer-reactive T-cell receptors from clinical samples

Abstract T-cell receptors can sense cancer-associated changes in cellular proteins, lipids, metabolites, and stress pathways, enabling immune-mediated tumour elimination in some patients. These receptors underpin T-cell receptor-based immunotherapies, yet their isolation from clinical samples remains challenging due to...

Marine E. Caillaud, C. Rius, Théo Morin et al. · 0 citations
Open access Sep 2026

29 Engineering CD16-Enhanced Stem Cell–Derived Universal NKT Cells to Potentiate Anti-CD70 Therapy in Renal Cell Carcinoma

CD16HSC-NKT cells are established as a versatile and scalable cellular platform that synergizes with cusatuzumab to enhance therapeutic efficacy against RCC, and represent a promising approach to overcoming current limitations of monoclonal antibody therapy and advancing next-generation immunotherapies for solid tumors...

Yan-Ruide Li, Yi-Chen Zhu, Yu-Ning Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.